Clinical Trials Logo

microRNA clinical trials

View clinical trials related to microRNA.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06037603 Recruiting - Exercise Clinical Trials

Dual-Task Exercise for Mild Traumatic Brain Injury (mTBI)

Start date: March 6, 2024
Phase: N/A
Study type: Interventional

The investigators previously developed a virtual 14-day dual-task walking exercise program and tested its feasibility with individuals with mild traumatic brain injury (mTBI) history. The investigators will test the feasibility and efficacy of a mobile app-version (Uplode) of the same 14-day exercise program (Brain & Walk Exercise Every Day [BraW-Day]), on cognition, sensorimotor, and other functions in a group of voluntary young adults with an mTBI between last three months to two years, including student athletes, Veterans, and ethnic minorities.

NCT ID: NCT05392348 Recruiting - Gut Microbiota Clinical Trials

Human Gut Microbiota and microRNA Expression

Start date: May 25, 2022
Phase: N/A
Study type: Interventional

In this study, stachyose was used as an intervention factor. We will evaluate changes in fecal gut microbiota and miRNA expression profiles in subjects under stachyose intervention

NCT ID: NCT04889053 Recruiting - Type 2 Diabetes Clinical Trials

Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)

Start date: June 1, 2021
Phase:
Study type: Observational

Coronary artery calcification (CAC) is a common complication of type 2 diabetes mellitus(T2DM), which can significantly increase all-cause mortality and the incidence of serious cardiovascular events, and increase the burden of the national economy. The epidemiological characteristics and the clinical progress of CAC are still not clear. Moreover, the pathogenesis of CAC has not yet been fully elucidated, and lack of specific diagnostic indicators. Arterial calcification is an active, reversible, and multifactorial biological process like bone formation. It is generally believed that early detection of calcification lesions and active targeted treatment may be the key to prevention and treatment of vascular calcification. In addition, statins are commonly used in patients with dyslipidemia and can stabilize CAC plaque. However, the timing, dosage and effect of statins are controversial. Moreover, our previous study found that the expression of miR-32 is significantly elevated in patients with CAC, and can promoting vascular calcification. Herein, this study is to conduct a prospective cohort study on T2DM patients with CAC in Hunan province through a multidisciplinary and multi-center cooperation model, the main research objectives include the following three parts: ① To identify the prevalence, incidence, and characteristics of CAC in T2DM patients in Hunan province, and to build a risk assessment model. ② To observe the effects of statins on the occurrence and development of CAC in patients with T2DM, and to provide clinical data for the improvement of medication guidelines; ③To observe the dynamic changes of serum miR-32 in the progression of CAC in patients with T2DM, and to explore its possibility as a serological diagnosis or prognostic bio-maker of CAC. The completion of this research project is expected to bring a new breakthrough in the field of early diagnosis, prognosis evaluation, and intervention treatment of patients with T2DM combined with CAC, and provide an important reference for the formulation of cardiovascular disease prevention and control strategy.

NCT ID: NCT02691286 Recruiting - Clinical trials for Acute Coronary Syndrome

Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock

Start date: February 2016
Phase: N/A
Study type: Observational

The aim of the study is knowing the prognostic value of circulating miRNAs in patients admitted to our hospital with STEMI complicated with cardiogenic shock.